Next Article in Journal
Computational Molecular Nanoscience Study of the Properties of Copper Complexes for Dye-Sensitized Solar Cells
Next Article in Special Issue
Determination of Homoarginine, Arginine, NMMA, ADMA, and SDMA in Biological Samples by HPLC-ESI-Mass Spectrometry
Previous Article in Journal
Identification and Characterization of the Actin-Binding Motif of Phostensin
Previous Article in Special Issue
Associations between Endogenous Dimethylarginines and Renal Function in Healthy Children and Adolescents
Open AccessReview

Asymmetric Dimethyarginine as Marker and Mediator in Ischemic Stroke

1
Department of Neurology, Hannover Medical School, 30623 Hannover, Germany
2
Department of Neurology, Huashan Hospital Fudan University, Shanghai 200040, China
3
Center for Systems Neuroscience (ZSN), 30559 Hannover, Germany
4
Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing 10050, China
5
Department of Nephrology and Hypertension, Hannover Medical School, 30623 Hannover, Germany
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2012, 13(12), 15983-16004; https://doi.org/10.3390/ijms131215983
Received: 28 September 2012 / Revised: 14 November 2012 / Accepted: 21 November 2012 / Published: 28 November 2012
(This article belongs to the Special Issue ADMA and Nitrergic System)
Asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase (NOS) inhibitor, is known as mediator of endothelial cell dysfunction and atherosclerosis. Circulating ADMA levels are correlated with cardiovascular risk factors such as hypercholesterolemia, arterial hypertension, diabetes mellitus, hyperhomocysteinemia, age and smoking. Accordingly, clinical studies found evidence that increased ADMA levels are associated with a higher risk of cerebrovascular events. After the acute event of ischemic stroke, levels of ADMA and its analog symmetric dimethylarginine (SDMA) are elevated through augmentation of protein methylation and oxidative stress. Furthermore, cleavage of ADMA through dimethylarginine dimethylaminohydrolases (DDAHs) is reduced. This increase of dimethylarginines might be predictive for adverse clinical outcome. However, the definite role of ADMA after acute ischemic stroke still needs to be clarified. On the one hand, ADMA might contribute to brain injury by reduction of cerebral blood flow. On the other hand, ADMA might be involved in NOS-induced oxidative stress and excitotoxic neuronal death. In the present review, we highlight the current knowledge from clinical and experimental studies on ADMA and its role for stroke risk and ischemic brain injury in the hyperacute stage after stroke. Finally, further studies are warranted to unravel the relevance of the close association of dimethylarginines with stroke. View Full-Text
Keywords: asymmetric dimethylarginine (ADMA); symmetric dimethylarginine (SDMA); nitric oxide (NO); nitric oxide synthase (NOS); ischemic stroke asymmetric dimethylarginine (ADMA); symmetric dimethylarginine (SDMA); nitric oxide (NO); nitric oxide synthase (NOS); ischemic stroke
MDPI and ACS Style

Chen, S.; Li, N.; Deb-Chatterji, M.; Dong, Q.; Kielstein, J.T.; Weissenborn, K.; Worthmann, H. Asymmetric Dimethyarginine as Marker and Mediator in Ischemic Stroke. Int. J. Mol. Sci. 2012, 13, 15983-16004.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop